Amgen/UCB Poised For Osteoporosis Drug Filing On Back Of Mixed PhIII

Amgen Inc. and partner UCB will file their osteoporosis drug romosozumab this year on the back of mostly positive Phase III data in postmenopausal women – but where will the drug be positioned against Amgen's own Prolia (denosumab) and other available treatments?

The Phase III FRAME study testing romosozumab, an investigational bone-forming monoclonal antibody, in postmenopausal women with osteoporosis met its co-primary endpoint of reducing the incidence of new vertebral fracture through months 12 and 24